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Abstract
Background Little is known about the role of cyclooxygenase (COX)-2 in gastroesophageal reflux disease (GERD) and the
development of Barrett’s metaplasia. The objectives of this study were to further analyze COX-2 mRNA expression in
patients with GERD compared to Barrett’s esophagus (BE) and Barrett’s cancer (BC).
Methods Tissue samples from 110 patients with GERD (n=43), BE (n=20), and BC (n=47) were obtained in routine upper
GI endoscopy. Expression levels of COX-2 were measured by quantitative real-time reverse trancriptase polymerase chain
reaction (RT-PCR). Also, 24-h pH monitoring was performed in all patients of the GERD study group and the DeMeester
composite score was used to match COX-2 mRNA expression with the severity of acid exposure in the lower esophagus.
Results COX-2 mRNA is progressively upregulated within the metaplasia–dysplasia–adenocarcinoma (MDA) sequence
(p=0.001). COX-2 levels of the squamous epithelium in the distal esophagus from patients with GERD and a pathologic
mean DeMeester score (>14.72) were significantly higher than in patients with normal DeMeester scores (p=0.01).
Conclusion In summary our findings suggest that alterations in COX-2 mRNA expression occur independently of endoscopic
or histologic signs of GERD in the acid-exposed squamous epithelium of the distal esophagus. However, this early COX-2
increase in GERD is further upregulated within the MDA sequence for yet unknown reasons.
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Introduction
Gastroesophageal reflux disease (GERD) is a common disease
that affects up to 30% of the Western population.1 It is
associated with esophageal adenocarcinoma, a rapidly in-
creasing cancer in the Western world.2–4 Cancer development
is a multistep process that starts with the mucosal injury of
the squamous epithelium of the distal esophagus by GERD
and progresses through intestinal metaplasia and dysplasia to
invasive adenocarcinoma.3 Molecular events associated with
the pathogenesis of esophageal adenocarcinoma have recently
been identified.5 Whereas most efforts have been directed at
the metaplasia–dysplasia–adenocarcinoma (MDA) sequence,
little is known about the molecular changes that occur in the
early progression of disease, i.e., the transformation of
squamous epithelium in the distal esophagus to metaplastic
Barrett’s epithelium.
Cyclooxygenase (COX) is the rate-limiting enzyme in
the conversion of arachidonic acid to prostaglandins. The
isoform COX-1 is thought to be constitutively expressed in
a variety of tissues, whereas COX-2 is induced by
cytokines, growth factors, mitogens, and oncoproteins.
COX-2 is involved in the regulation of a broad range of
cellular processes, including angiogenesis, apoptosis, and
cell proliferation. Recently, overexpression of COX-2 has
been reported in various types of tumors, including
esophageal adenocarcinoma.6–8 Several studies revealed
an increased COX-2 expression in the MDA sequence,
suggesting COX-2 to be involved Barrett’s cancer (BC)
development.9–11
Less is known about the role of COX-2 in the initial
phase, the conversion of squamous epithelium to Barrett’s
metaplasia. Whereas studies dealing with severe reflux in
rodents confirmed that inhibition of COX-2 with selective
inhibitors resulted in a reduced incidence of intestinal
metaplasia and cancer development, further insights in the
process of COX-2 upregulation at the earliest stages of
esophageal carcinogenesis might lead to new therapeutic
strategies for patients with GERD.
To further elucidate the role of COX-2 in GERD and
Barrett’s development, we analyzed the mRNA expression
in biopsy specimens of GERD patients with and without the
presence of Barrett’s metaplasia.
Material and Methods
Patients
Tissue samples of 110 consecutive patients with GERD,
Barrett’s esophagus (BE), and BC were obtained at upper
GI endoscopy between June 1997 and November 2002. For
normal tissue controls, for each study group paired biopsies
from the proximal esophagus were obtained. Biopsy speci-
mens were immediately bisected and snap-frozen in liquid
nitrogen and stored at −70°C until further processing. One
biopsy half was routinely fixed in 4% buffered formalin and
paraffin-embedded overnight. Representative sections (be-
ginning, middle, and end of sectioning) were stained with
hematoxylin and eosin by a standard method and were
examined by two experienced staff pathologists. For total
RNA extraction and reverse trancriptase polymerase chain
reaction (RT-PCR), fresh frozen biopsy halves were used
without performing laser-captured microdissection.
Detailed clinicopathologic data of the GERD, BE, and
BC group are shown in Tables 1, 3, and 4.
(1) GERD group: Patients were considered to have
gastroesophageal reflux based on the presence of
typical reflux symptoms, which included heartburn,
regurgitation, and epigastric pain. None of the GERD
study patients showed atypical symptoms of GERD,
such as new-onset bronchial asthma, chronic cough,
and symptomatology from ear, nose, and throat regions.
Tissue samples from 43 patients of squamous epithe-
lium from the distal and proximal esophagus were
taken. Twenty (47.5%) patients had positive 24-h pH
studies, 35 (81.4%) had evidence of histologic esoph-
agitis, and 33 (76.8%) had endoscopic signs of
esophagitis (Tables 1 and 2).
(2) Barrett’s esophagus group: Samples were from 20
patients with histologically confirmed BE. Squamous
epithelium from the proximal esophagus was collected
as paired control tissue. Fifteen (75%) patients had no
dysplasia, 4 (20%) had low grade dysplasia, and 1
Table 1 Clinicopathologic Parameters of GERD Patients
Parameters
Patients (n)
Total 43
Male 15 (34.9%)
Female 28 (65.1%)
Median age in years (min–max) 52.9 (17.7–82.5)
DeMeester Score (pH)14
<14.72 23 (52.5%)
>14.72 20 (47.5%)
Histology13
Grade 0 8 (18.6%)
Grade 1 26 (60.5%)
Grade 2 6 (13.9%)
Grade 3 3 (7.0%)
Endoscopy24
Grade 0 10 (23.2%)
Grade 1 23 (53.5%)
Grade 2 6 (14.0%)
Grade 3 4 (9.3%)
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(5%) patient had high-grade dysplasia. Patients with
evidence of dysplasia were not included in the
statistical analysis because of low patient numbers
(Table 3).
(3) Barrett’s cancer group: Samples were from 47 patients
showing esophageal adenocarcinoma in BE. Normal
squamous epithelium was taken from the proximal
esophagus as paired control tissue (Table 4).
Informed consent was obtained from each patient in
accordance to the requirements of our institution’s board of
ethics.
Definition of Reflux Esophagitis by Endoscopy
and Histopathology
The criteria by Savary and Miller12 were used to define
endoscopic GERD into grades I–IV. Morphologic criteria
reported by Elster13 were applied for histopathologic classi-
fication of reflux esophagitis into grades 0–3 (Tables 1 and 2).
All tissue specimens were evaluated by two experienced
staff pathologists (S.E.B. and U.D.).
PH Monitoring
Twenty-four-hour pH monitoring was performed by posi-
tioning a glass pH electrode (Medtronic Inc., Minneapolis,
MN, USA) 5 cm above the manometrically measured upper
border of the lower esophageal sphincter. The electrode was
connected to a digital recording device (Medtronic Inc./
Synectics Medical, EsopHogram Reflux Analysis, version
2.01, Minneapolis, MN, USA) and the pH was continuous-
ly monitored for 24 h. The following parameters were
measured: total percentage of time with pH less than 4,
percentage of time the pH was less than 4 when subject was
upright, percentage of time the pH was less than 4 when
subject was supine, total number of GERD episodes longer
than 5 min, time of the longest GERD episode, and
composite score based on these parameters.14
Table 2 Distribution of the DeMeester Score with Histologic and Endoscopic Signs of Reflux
DeMeester score Histology (n)13 Endoscopy (n)24
Grade 0 Grade 1 Grade 2 Grade 3 Grade 0 Grade 1 Grade 2 Grade 3
<14.72 (n=23) 6a 14 2 1 8a 12 3 0
>14.72 (n=20) 2 12 4 2 2 11 3 4
a No patient was negative for histology and endoscopy at the same time.
Table 3 Clinicopathologic Parameters of Barrett’s Patients
Parameters
Patients (n)
Total 20
Male 17 (85%)
Female 3 (15%)
Median Age (min–max) 58.9 (20.6–81.3)
Barrett’s length (n)
<1 cm (ultrashort) 5 (25%)
1–3 cm (short) 7 (35%)
>3 cm (long) 8 (40%)
Dysplasia (n)
No dysplasia 15 (75%)
Low-grade dysplasia 4 (20%)
High grade dysplasia 1 (5%)
Table 4 Clinicopathologic Parameters of BC Patients
Parameters
Patients (n)
Total 47 (85.1%)
Male 45 (95.7%)
Female 2 (4.3%)
Median Age (min./max.) 60.9 (41.4–81.2)
Residual tumor category
R0 40 (85.1%)
R1 0 (0%)
R2 1 (2.1%)
not resected 6 (12.8%)
c/pT category
T1 20 (42.6%)
T2 12 (25.5%)
T3 14 (29.8%)
T4 1 (2.1%)
c/pN category
N0 29 (61.7%)
N1 18 (38.3%)
c/pM category
M0 38 (80.9%)
M1a 5 (10.6%)
M1b 4 (8.5%)
Grading
G1 3 (6.4%)
G2 33 (70.2%)
G3 11 (23.4%)
Tumor–Node–Metastasis (pTNM) Pathological Classification: c/pT =
primary tumor, c/pN = regional lymph node metastasis, c/pM = distant
metastasis, G = grade of differentiation, R = residual tumor category
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RNA Isolation and cDNA Synthesis
Biopsy specimens were bisected and snap-frozen in liquid
nitrogen. Representative sections (beginning, middle, and
end of sectioning) were stained with hematoxylin and eosin
by a standard method and examined by two experienced
staff pathologists.
Total RNA was isolated from fresh frozen biopsy halves
using the Trizol-Kit (Life Technologies/GIBCO, Grand
Island, NY, USA) according to the manufacturer’s instruc-
tions. After the generation of cDNA using oligo (dT)18
primers and Moloney murine leukemia virus reverse
transcriptase (Clontech Advantage™ Kit, Clontech Lab.
Inc., Palo Alto, CA, USA), direct quantitative real-time RT-
PCR (TaqMan™, ABI PRISM 7900HT Sequence Detec-
tion System Applied Biosystems, Darmstadt, Germany)
assays were performed in triplicates to determine COX-2
mRNA expression levels.
Quantitative Real-time RT-PCR
The primers and probes for COX-2 used in the study were
previously reported.15 Thermal cycling conditions for
COX-2 were 120 s at 50°C and 10 min at 95°C for initial
denaturation followed by 40 cycles at 95°C for 15 s and
60°C for 60 s. We used serial dilutions of standard cDNA
synthesized from human placenta total cellular RNA
(Clontech Lab. Inc.). Triplicates of the tissue samples were
assayed in each run. COX-2 levels were standardized with
β-actin (ratio COX-2/β-actin) to account for loading
differences. Gene expression levels (mRNA) were reported
using the median as point estimator and the range of values.
Statistical Analysis
COX-2 mRNA levels and endoscopic and histopathological
data were analyzed by nonparametric testing (Wilcoxon
rank test, Mann–Whitney test, Kruskal–Wallis test, and
Friedmann test). The level of significance was set to p<
0.05 and p values are given for two-sided testing. All
statistical tests were performed using the software package
SPSS for Windows, version 11.0, Chicago, IL, USA.
Results
COX-2 Expression in Different Study Groups
COX-2 mRNA expression was detectable by quantitative
real-time RT-PCR in all 110 tissue samples. According to the
histopathologic group, median COX-2mRNA expressionwas
lowest in normal squamous epithelium of the distal esophagus
(median 0.35, range 0.08–7.8), intermediate in BE (median
0.86, range 0.08–9.61), and highest in esophageal adenocar-
cinoma (median 1.62, range 0.001–99.21) (p=0.001). The
median value and range of expression levels of COX-2
mRNA in the three study groups are listed in Table 5.
In patients with BE without dysplasia, COX-2 expres-
sion was significantly higher in metaplastic tissue compared
to paired normal squamous epithelium (p=0.03).
Esophageal cancer patients had higher COX-2 mRNA
expression levels in cancer tissues compared to paired
normal squamous epithelium and BE (p=0.001).
The mean COX-2 mRNA expression of squamous epithe-
lium in all three study groups did not show any significant
difference (p=0.10). Furthermore, COX-2 mRNA expression
in biopsy specimens obtained from histologically and
endoscopically classified GERD did not show a significant
difference in distal acid-exposed tissues and paired squamous
epithelium control tissues (p=0.63). No significant difference
in COX-2 mRNA expression of metaplastic Barrett’s
epithelium in patients with BE and patients with BC was
detected (p=0.29).
COX-2 Expression and Clinicopathological Factors
of Patients with GERD
Biopsy specimens obtained from patients with a mean
DeMeester score >14.72 showed significantly upregulated
median COX-2 mRNA levels in the distal acid-exposed
(p=0.01) esophagus compared with patients having a
Table 5 COX-2 mRNA Expression in Study Groups
Median Min Max p value
GERDa (n=43) Proximal (n=39) 0.3835 0.1058 5.9145 0.63
Distal (n=43) 0.3562 0.0853 7.8081
BE (n=15) Squamous epithelium (n=10) 0.4412 0.0754 2.0350 0.03
Intestinal metaplasia (n=15) 0.8600 0.0838 9.6151
Barrett’s adenocarcinoma (n=47) Squamous epithelium (n=38) 0.2824 0.0001 3.0755 0.001
Intestinal metaplasia (n=15) 1.2295 0.2689 8.8384
Barrett’s carcinoma (n=45) 1.6210 0.0001 99.218
a Defined by clinical reflux symptoms and positive histology and/or endoscopy
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negative DeMeester score (Fig. 1). No significant correla-
tion was detected between COX-2 expression and endo-
scopic or histologic findings (p=0.63) (Table 5).
COX-2 Expression and Clinicopathological Factors
of Patients with Barrett’s Adenocarcinoma
Overexpression of COX-2 mRNA in patients with Barrett’s
adenocarcinoma was not associated with grading (p=0.58),
T category (p=0.95), N category (p=1.0), or patients’
survival (log-rank test, p=0.70).
Discussion
We present a study on mRNA expression of COX-2 in the
reflux MDA sequence. We could reconfirm that progression
of BE to esophageal adenocarcinoma is accompanied by an
increase in COX-2 expression as reported by other
groups.10,11 As previously described by Hamoui et al., we
could demonstrate that COX-2 expression was significantly
correlated with exposure of the distal esophagus to acid
reflux, suggesting alteration of COX-2 expression to be one
of the earliest specific changes in the reflux MDA
sequence.
Epidemiologic studies revealed that the use of COX-2
inhibitors was associated with a decreased risk for
esophageal cancer. Much interest was focused on the
potential role of COX-2 in esophageal carcinogenesis.7,8
Previous studies analyzed the expression pattern of COX-2
in the MDA sequence. Our group recently demonstrated
that COX-2 protein expression by immunohistochemistry
was progressively increased in metaplastic, dysplastic, and
cancer tissue with the most significant differences between
squamous epithelium and metaplasia and from low-grade to
high-grade dysplasia.16 Kuramochi et al.9 measured the
gene expression of COX-2 by real-time quantitative
polymerase chain reaction in the pathogenesis of Barrett’s
adenocarcinoma and also showed a stepwise increase of
COX-2 mRNA expression at the different stages. Our
results are in agreement with these findings, showing that
median COX-2 mRNA expression is stepwise upregulated
in Barrett’s metaplasia and adenocarcinoma.
The development of esophageal adenocarcinoma is a
multistep process that starts with the mucosal injury of the
squamous epithelium of the distal esophagus by GERD and
progresses through intestinal metaplasia, dysplasia, to
cancer.2,3 Whereas several molecular events associated with
the progression from metaplastic to cancer tissue have been
identified in recent years, little is known about the
molecular changes that occur in the beginning of disease.5
This first step, conversion of squamous mucosa to
columnar mucosa, is perhaps the most critical because
adenocarcinoma cannot develop within squamous mucosa.3
Therefore, we additionally examined COX-2 mRNA
expression in esophageal biopsies from patients with
GERD. We were able to show that COX-2 expression in
biopsies obtained from patients with a positive DeMeester
score >14.72 was significantly upregulated compared to
patients with a negative DeMeester score. These findings
are in agreement with a recent study by Hamoui et al.17 In
their study, expression levels of several known genes were
compared with the degree of acid exposure in the lower
esophagus found on 24-h esophageal pH monitoring of 61
patients with GERD. They demonstrated that the expression
levels of COX-2 correlated positively with the 24-h pH
score, whereas there was no correlation between the
expression of other tested genes and esophageal acid
Figure 1 COX-2 mRNA in
GERD associated to DeMeester
score.
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exposure. Therefore, acid reflux disease alters gene expres-
sion in esophageal mucosa, and leads to overexpression of
COX-2, representing one of the earliest changes associated
with gastroesophageal reflux, because in our study the
increase in COX-2 expression was independent of the
endoscopic or histologic findings in the squamous mucosa.
To examine the specificity of this observation, we addi-
tionally examined COX-2 mRNA expression in paired
specimens derived from proximal esophageal tissue sam-
ples, which appeared “normal” on endoscopy and histopa-
thology, although cervical 24-h pH monitoring was not
performed. Our GERD study patients showed no clinical
symptoms of cervical or extra esophageal reflux disease,
suggesting that the proximal esophageal epithelium was not
exposed to acid reflux. Although dual channel 24-h pH
monitoring was not performed, our data suggest that COX-2
mRNA expression was significantly upregulated only in the
acid-exposed squamous epithelium of the distal esophagus. A
field effect as shown for other genes18 could not be detected
in our study, thus indicating that COX-2 upregulation is
probably an immediate response to acid exposure in the
distal esophagus rather than a genetic variation of the entire
esophagus.
Chemoprevention strategies might therefore be applied
earlier in the neoplastic process because the use of selective
COX-2 inhibitors might prevent progression of disease at
an early stage.19–21 In fact, studies about severe reflux in
rodents confirmed that inhibition of COX-2 with selective
inhibitors resulted in a reduced rate of intestinal metaplasia
and cancer development.22,23
Large prospective trials with the inclusion of cervical
24-h pH monitoring are needed to validate these preliminary
findings.
Conclusion
In summary our findings suggest that alterations in COX-2
mRNA expression occur independently of endoscopic or
histologic signs of GERD in the acid-exposed squamous
epithelium of the distal esophagus. However, this early
COX-2 increase in GERD is further upregulated in Barrett’s
metaplasia and BC development for yet unknown reasons.
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